OPTN

OptiNose, Inc. (OPTN) | Rumor.io

OptiNose

OPTN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about OPTN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 21

OPTN closed 52% higher yesterday following M&A news of a ~$330M acquisition by Paratek Pharmaceuticals.
Piper Sandler downgraded OPTN from $15 to $9 with a Neutral rating, citing a decrease in potential downside.
HC Wainwright & Co. also downgraded OPTN to Neutral with a target price of $9, following the acquisition news.

Generated by AI

Sentiment

Of the messages about OPTN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	40% -40.79
Bearish	—	—	—	60% +40.79

Bullish· Mar 20

OptiNose, Inc. ($OPTN) has agreed to be acquired by Paratek Pharmaceuticals in a deal valued at up to $330 million or $9/share in cash plus up to $5 per share in contingent value rights (CVRs).
The acquisition is expected to provide a significant boost to $OPTN's value, with the stock already seeing a 60% premarket gain in response to the news.
The deal includes a 1-for-15 reverse split completed last quarter for Nasdaq compliance, which may have contributed to the stock's strong momentum and high relative strength.

Bearish· Nov 16

$OPTN's recent offering priced at $1.60/share is 1/3 below the company's 52-week low, suggesting undervaluation.
The offering has led to new all-time lows for the company, even in a raging bull market, indicating a significant decline in investor confidence.
The low pricing of the offering may have allowed insiders to buy back shares at a discounted price, potentially at the expense of retail investors.

Generated by AI

Topics

Of the messages about OPTN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	72.41%
Controversies	—	—	—	0%
Earnings	—	—	—	20.69%
Macro	—	—	—	0%
Technical Analysis	—	—	—	6.9%

Earnings· Nov 27

OptiNose, Inc. ($OPTN) reported a Q3 EPS loss of $4.23, missing consensus estimates of ($0.47).
This represents a significant earnings miss for the company.
The actual loss of $4.23 is a substantial increase from the expected loss.

Announcements· Mar 20

Paratek Pharmaceuticals will acquire Optinose in a $330M transaction, with consideration payable to shareholders of up to $14 per share.
The deal includes the approved product Xhance and contingent value rights tied to future commercial milestones, with potential payments of up to $5 per share.
The acquisition is expected to close as early as mid-2025, subject to customary closing conditions, including approval by Optinose shareholders and receipt of required regulatory clearances.

Generated by AI

Community

Of the messages about OPTN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	18.97%
Newcomers	—	—	—	81.03%

Regulars· Dec 31

Five no-brainer AI stocks to buy in 2025 include OptiNose, Inc. ($OPTN) for its innovative products and strong growth potential.
OptiNose, Inc. ($OPTN) is mentioned as one of the companies that could benefit from the growing demand for AI-driven solutions in healthcare and biotech.
OptiNose, Inc. ($OPTN) is compared to Ehave ($EHVVF) as a stock that could be making a comeback, with both companies potentially benefiting from the growing demand for innovative healthcare solutions.

Newcomers· Apr 25

New investors are optimistic about OptiNose, Inc. ($OPTN) due to its expected peak XHANCE net revenues exceeding $300 million.
The company's recent corporate update and announcement of preliminary first-quarter XHANCE net revenue of $14.9 million has led to increased interest in the stock.
Many newcomers are taking advantage of lower prices to buy into $OPTN, with some even adding to their positions after the company's conference call.

Generated by AI

Also Discussed

Investors talking about OPTN also mention

#	Name	Attention
1	UroGen Pharma Ltd.URGN	0%new
2	Journey Medical Corp. Common StockDERM	0%0
3	CKPT - Checkpoint Therapeutics, Inc.	——
4	AVDL - Avadel Pharmaceuticals plc	——
5	Phathom Pharmaceuticals, Inc.PHAT	0%new
6	Unicycive Therapeutics Inc.UNCY	0%new
7	Milestone Pharmaceuticals Inc.MIST	0%+0
8	Karyopharm Therapeutics Inc.KPTI	0%new
9	VRNA - Verona Pharma plc	——
10	Mirum Pharmaceuticals, Inc.MIRM	0%0

OptiNose, Inc.

Location

Social

What share of all stock conversation is about OPTN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 21

OPTN closed 52% higher yesterday following M&A news of a ~$330M acquisition by Paratek Pharmaceuticals.
Piper Sandler downgraded OPTN from $15 to $9 with a Neutral rating, citing a decrease in potential downside.
HC Wainwright & Co. also downgraded OPTN to Neutral with a target price of $9, following the acquisition news.

Generated by AI

Sentiment

Of the messages about OPTN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	40% -40.79
Bearish	—	—	—	60% +40.79

Bullish· Mar 20

OptiNose, Inc. ($OPTN) has agreed to be acquired by Paratek Pharmaceuticals in a deal valued at up to $330 million or $9/share in cash plus up to $5 per share in contingent value rights (CVRs).
The acquisition is expected to provide a significant boost to $OPTN's value, with the stock already seeing a 60% premarket gain in response to the news.
The deal includes a 1-for-15 reverse split completed last quarter for Nasdaq compliance, which may have contributed to the stock's strong momentum and high relative strength.

Bearish· Nov 16

$OPTN's recent offering priced at $1.60/share is 1/3 below the company's 52-week low, suggesting undervaluation.
The offering has led to new all-time lows for the company, even in a raging bull market, indicating a significant decline in investor confidence.
The low pricing of the offering may have allowed insiders to buy back shares at a discounted price, potentially at the expense of retail investors.

Generated by AI

Topics

Of the messages about OPTN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	72.41%
Controversies	—	—	—	0%
Earnings	—	—	—	20.69%
Macro	—	—	—	0%
Technical Analysis	—	—	—	6.9%

Earnings· Nov 27

OptiNose, Inc. ($OPTN) reported a Q3 EPS loss of $4.23, missing consensus estimates of ($0.47).
This represents a significant earnings miss for the company.
The actual loss of $4.23 is a substantial increase from the expected loss.

Announcements· Mar 20

Paratek Pharmaceuticals will acquire Optinose in a $330M transaction, with consideration payable to shareholders of up to $14 per share.
The deal includes the approved product Xhance and contingent value rights tied to future commercial milestones, with potential payments of up to $5 per share.
The acquisition is expected to close as early as mid-2025, subject to customary closing conditions, including approval by Optinose shareholders and receipt of required regulatory clearances.

Generated by AI

Community

Of the messages about OPTN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	18.97%
Newcomers	—	—	—	81.03%

Regulars· Dec 31

Five no-brainer AI stocks to buy in 2025 include OptiNose, Inc. ($OPTN) for its innovative products and strong growth potential.
OptiNose, Inc. ($OPTN) is mentioned as one of the companies that could benefit from the growing demand for AI-driven solutions in healthcare and biotech.
OptiNose, Inc. ($OPTN) is compared to Ehave ($EHVVF) as a stock that could be making a comeback, with both companies potentially benefiting from the growing demand for innovative healthcare solutions.

Newcomers· Apr 25

New investors are optimistic about OptiNose, Inc. ($OPTN) due to its expected peak XHANCE net revenues exceeding $300 million.
The company's recent corporate update and announcement of preliminary first-quarter XHANCE net revenue of $14.9 million has led to increased interest in the stock.
Many newcomers are taking advantage of lower prices to buy into $OPTN, with some even adding to their positions after the company's conference call.

Generated by AI

OptiNose

Social

Mar 21

Sentiment

Bullish· Mar 20

Bearish· Nov 16

Topics

Earnings· Nov 27

Announcements· Mar 20

Community

Regulars· Dec 31

Newcomers· Apr 25

Also Discussed

OptiNose, Inc.

Company Information

Location

Also Discussed

Social

Mar 21

Sentiment

Bullish· Mar 20

Bearish· Nov 16

Topics

Earnings· Nov 27

Announcements· Mar 20

Community

Regulars· Dec 31

Newcomers· Apr 25